Literature DB >> 33632832

SARS-CoV-2 dependence on host pathways.

Jason P Wong1,2, Blossom Damania3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33632832     DOI： 10.1126/science.abg6837

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  10 in total

1.  Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19.

Authors:  Ji Hoon Ahn; JungMo Kim; Seon Pyo Hong; Sung Yong Choi; Myung Jin Yang; Young Seok Ju; Young Tae Kim; Ho Min Kim; M D Tazikur Rahman; Man Ki Chung; Sang Duk Hong; Hosung Bae; Chang-Seop Lee; Gou Young Koh
Journal:  J Clin Invest       Date:  2021-07-01       Impact factor: 14.808

2.  Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (Mpro).

Authors:  Alaa M Elgohary; Abdo A Elfiky; Florbela Pereira; Tarek Mohamed Abd El-Aziz; Mansour Sobeh; Reem K Arafa; Amr El-Demerdash
Journal:  Comput Biol Med       Date:  2022-06-17       Impact factor: 6.698

Review 3.  Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2.

Authors:  Long G Wang; Luxi Wang
Journal:  Immunotargets Ther       Date:  2022-05-18

Review 4.  Integrating evolutionary aspects into dual-use discussion: the cases of influenza virus and enterohemorrhagic Escherichia coli.

Authors:  Noble Selasi Gati; Ozan Altan Altinok; Sriram Kumar; Verónica A Ferrando; Joachim Kurtz; Michael Quante; Stephan Ludwig; Alexander Mellmann
Journal:  Evol Med Public Health       Date:  2021-10-26

Review 5.  An update of anti-viral treatment of COVID-19

Authors:  Serap Şimşek-Yavuz; Feride Ipek Komsuoğlu Çelikyurt
Journal:  Turk J Med Sci       Date:  2021-12-17       Impact factor: 0.973

Review 6.  Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2.

Authors:  Brian F Niemeyer; Kambez H Benam
Journal:  Pharmacol Ther       Date:  2021-10-28       Impact factor: 13.400

Review 7.  Promising Assays for Examining a Putative Role of Ribosomal Heterogeneity in COVID-19 Susceptibility and Severity.

Authors:  Yih-Horng Shiao
Journal:  Life (Basel)       Date:  2022-01-28

Review 8.  Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.

Authors:  Lei Zhao; Song Li; Wu Zhong
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

9.  Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice.

Authors:  Alvaro A Ordonez; C Korin Bullen; Andres F Villabona-Rueda; Elizabeth A Thompson; Mitchell L Turner; Vanessa F Merino; Yu Yan; John Kim; Stephanie L Davis; Oliver Komm; Jonathan D Powell; Franco R D'Alessio; Robert H Yolken; Sanjay K Jain; Lorraine Jones-Brando
Journal:  Commun Biol       Date:  2022-03-18

10.  A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.

Authors:  Tirosh Shapira; I Abrrey Monreal; Sébastien P Dion; David W Buchholz; Brian Imbiakha; Andrea D Olmstead; Mason Jager; Antoine Désilets; Guang Gao; Mathias Martins; Thierry Vandal; Connor A H Thompson; Aaleigha Chin; William D Rees; Theodore Steiner; Ivan Robert Nabi; Eric Marsault; Julie Sahler; Diego G Diel; Gerlinde R Van de Walle; Avery August; Gary R Whittaker; Pierre-Luc Boudreault; Richard Leduc; Hector C Aguilar; François Jean
Journal:  Nature       Date:  2022-03-28       Impact factor: 69.504
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.